Business Context and Reporting Period
This Form 8-K reports on the results of the 2016 Annual Meeting of Stockholders held by Galectin Therapeutics Inc. on December 15, 2016. The filing details the election of directors, the approval of executive compensation, and the ratification of the independent auditor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding corporate governance events and does not contain financial statement data.
Material Changes and Voting Results
The primary material event reported is the outcome of shareholder votes at the annual meeting:
- Election of Directors: All eight nominated directors were re-elected. Votes for ranged from approximately 10.67 million to 11.00 million, with votes withheld ranging from approximately 247,000 to 573,000. There were 14,976,838 broker non-votes for each director.
- Executive Compensation: The non-binding advisory resolution to approve executive compensation passed with 10,263,034 votes for, 844,997 votes against, and 142,823 abstentions.
- Auditor Ratification: The selection of Cherry Bekaert LLP as the independent registered public accounting firm for the year ending December 31, 2016, was ratified with 25,457,842 votes for, 533,163 votes against, and 236,687 abstentions.
- Series B Preferred Stock Directors: James C. Czirr was re-elected and Theodore Zucconi was elected as Series B Directors. Both received 6,356,932 votes for with zero votes withheld.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The report is limited to the disclosure of voting results.
Investor Verification Checklist
- Verify the total number of shares outstanding and the percentage of votes represented by the "For" votes to assess the level of shareholder support.
- Confirm the specific terms of the Series B Convertible Preferred Stock to understand the voting power exercised by that class.
- Review the full proxy statement for the 2016 Annual Meeting to understand the context of the executive compensation package approved.
- Check subsequent filings (10-K or 10-Q) for the financial metrics absent from this 8-K.